Cases & Deals

  • Home
  • Practices
  • GenScript Bio's non-wholly-owned subsidiary Probio Technology Limited raises $37 million in Series B financing

Share

GenScript Bio's non-wholly-owned subsidiary Probio Technology Limited raises $37 million in Series B financing

July 2022

Client(s) GenScript Biotech Corporation

Jones Day represented GenScript Biotech Corporation (HK Stock Code: 1548) ("GenScript Biotech") in the $37 million Series B financing of non-wholly-owned subsidiary Probio Technology Limited ("Probio Cayman"), led by Zhenjiang High-tech Venture Capital (HK) Limited.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.